Меню
Идёт набор NCT05528939

Feasibility/Acceptability of Attentional-Control Training in Survivors

Без фазы С лечением Pediatric Cancer Pediatric ALL Pediatric Brain Tumor Attention Difficulties

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: EndeavorRx, Control video game.
Кому может быть актуально
Состояния в реестре: Pediatric Cancer, Pediatric ALL, Pediatric Brain Tumor, Attention Difficulties. Базовые параметры: 8 лет — 16 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
США
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

FAACTS: Feasibility/Acceptability of Attentional-Control Training in Survivors

Обзор

This is a multicenter pilot randomized controlled trial, with an active control condition, of the feasibility, acceptability, and preliminary efficacy of EndeavorRx in a cohort of survivors of acute lymphoblastic leukemia or brain tumor ages 8-16 who are \> 1 year from the end of therapy.

Подробное описание

Survival rates are increasing for common pediatric cancers, including acute lymphoblastic leukemia (ALL) and brain tumors; yet, the life-saving treatments for these cancers place survivors at heightened risk for sustained cognitive effects. Longitudinal research has shown that the cognitive burden of ALL and pediatric brain tumors often consists of impairments in attention, working memory, and executive functioning, which can result in long-term disruption to daily living, socialization, academic achievement, and quality of life. Few non-pharmacological interventions exist to ameliorate these cognitive late effects. EndeavorRx, an FDA-approved electronic attentional-control training program, may be one intervention to help remediate executive functioning difficulties experienced by survivors. Although the program has been efficacious for youth with Attention-Deficit/Hyperactivity Disorder (ADHD), it has not yet been tested among survivors of childhood ALL or brain tumor. We propose to assess the feasibility, acceptability, and preliminary efficacy of EndeavorRx in a pilot randomized, controlled trial. Survivors of ALL or brain tumor who are between the ages of 8 and 16 and have been off-therapy for at least one year will be included. The goal is to enroll and screen approximately 50 survivors across three pediatric oncology centers, in order to identify 40 participants with attention difficulties who will be randomized to one of two treatment arms. Participants will be assigned to either the EndeavorRx intervention, which includes 25-30 minute sessions per day, 5 days per week, for one month, or an active control condition of the same duration and intensity. Patients will undergo neurocognitive testing pre- and post-intervention, and parents will complete questionnaires regarding their child's functioning. It is hypothesized that this attentional-control training program will be both acceptable and feasible, with sufficient enrollment, positive satisfaction ratings, and acceptable treatment adherence. It is also anticipated that participants will show increases in performance-based and parent-rated attention, as compared to those in the active control condition.

Вмешательства

  • Устройство EndeavorRx
    EndeavorRx is a digital intervention delivered through an action video game that is indicated to improve attention function. EndeavorRx users first complete two discrete tasks: 1) a perceptual discrimination/attention task in which users respond to target stimuli and ignore distractor stimuli (e.g., tapping the screen quickly only when red aliens appear) and 2) a sensorimotor navigation task in which users tilt their device to steer a hovercraft down a river while targeting or avoiding certain o
  • Другое Control video game
    The active control program, used in previous studies of this intervention, was designed to match EndeavorRx on expectancy, engagement, and time on task in the form of a challenging and engaging digital word game, targeting cognitive domains not targeted by EndeavorRx and not primarily associated with attentional difficulties. Users are instructed to find and connect letters on a grid to spell words; points are awarded based on number of words formed, word length, and the use of unusual letters.

Первичные конечные точки

  • Feasibility assessed by patient/family interest [Срок оценки: Baseline]
  • Feasibility assessed by EndeavorRx training adherence rates [Срок оценки: After completion of 4 weeks of EndeavorRx training]
  • Feasibility assessed by reports of technical ease-of-use and satisfaction [Срок оценки: End of training (+4 weeks)]
Вторичные конечные точки (8)
  • Change from baseline inattention assessed by Omission Errors on the Conners' Continuous Performance Test, 3rd Edition (CPT-3) at end of training [Срок оценки: Baseline and end of training (+4 weeks)]
  • Change from baseline inattention assessed by Omission Errors on the Conners' Continuous Performance Test, 3rd Edition (CPT-3) at 4-month follow-up (16 weeks post-training/control +/- 4 weeks) [Срок оценки: Baseline and 4 months after end of training (16 weeks post-training/control +/- 4 weeks)]
  • Change from baseline inattention assessed by the ADHD Rating Scale, Fifth Edition (ADHD-RS-5) Inattention subscale at end of training [Срок оценки: Baseline and end of training (+4 weeks)]
  • Change from baseline inattention assessed by the ADHD Rating Scale, Fifth Edition (ADHD-RS-5) Inattention subscale at 4-month follow-up (16 weeks post-training/control +/- 4 weeks) [Срок оценки: Baseline and 4 months after end of training (16 weeks post-training/control +/- 4 weeks)]
  • Change from baseline inhibitory control assessed by the Behavior Rating Inventory of Executive Functioning, Second Edition (BRIEF-2) Inhibit subscale at end of training [Срок оценки: Baseline and end of training (+4 weeks)]
  • Change from baseline inhibitory control assessed by the Behavior Rating Inventory of Executive Functioning, Second Edition (BRIEF-2) Inhibit subscale at 4-month follow-up (16 weeks post-training/control +/- 4 weeks) [Срок оценки: Baseline and 4 months after end of training (16 weeks post-training/control +/- 4 weeks)]
  • Change from baseline executive functioning assessed by the Behavior Rating Inventory of Executive Functioning, Second Edition (BRIEF-2) Cognitive Regulation Index (CRI) at end of training [Срок оценки: Baseline and end of training (+4 weeks)]
  • Change from baseline executive functioning assessed by the Behavior Rating Inventory of Executive Functioning, Second Edition (BRIEF-2) Cognitive Regulation Index (CRI) at end of training [Срок оценки: Baseline and 4 months after end of training (16 weeks post-training/control +/- 4 weeks)]

Критерии участия

Критерии включения

  • Aged 8-16 years at time of screening.
  • History of diagnosis of acute lymphoblastic leukemia (ALL) or brain tumor (BT).
  • At least 1 year from completion of planned therapy and stable from a disease standpoint.
  • Participating child and caregiver are fluent in spoken English.
  • Availability of a caregiver who is willing and capable of providing support and supervision during cognitive training.
  • Participating child is either not taking any prescribed stimulant medication for attention difficulties or has been prescribed a stable dose of stimulant medication for attention difficulties for at least 30 days prior to enrollment.
  • Only patients with a T-score ≥ 75th percentile on the CPT-3 Omission Errors scale or on the BRIEF-2 Cognitive Regulation Index will be randomized.

Критерии исключения

  • A history of photosensitive seizures.
  • A motor, visual, or auditory handicap that prevents computer use.
  • A mental health condition that precludes, or takes treatment precedence over, participation in the cognitive training.
  • Participants identified during the baseline assessment as having a full-scale IQ < 80, as estimated by WASI-II (Vocabulary and Matrix Reasoning), will not be randomized.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Простое слепое
Основная цель
Лечение

Центры проведения

США · 1 центр
  • Children's National Hospital — Washington D.C.

Идентификаторы

NCT: NCT05528939 · STUDY00000150 · R21CA261877

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗